Q4 2024 Earnings Call Transcript March 4, 2025 NeuroPace, Inc. beats earnings expectations. Reported EPS is $-0.18, ...

Quarterly revenue grew 19% year-over-year to $21.5 million in the fourth quarter of 2024 Full year 2024 revenue increased 22% to $79.9 million compared with $65.4 million in 2023; revenue grew more ...

Revenue: US$79.9m (up 22% from FY 2023). Net loss: US$27.1m (loss narrowed by 18% from FY 2023). US$0.93 loss per share ...

MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced ...

Shares of NeuroPace stock opened at $12.95 on Friday. The business’s fifty day simple moving average is $12.69 and its 200 day simple moving average is $9.66. The firm has a market ...

NeuroPace, Inc., a medical device company dedicated to improving the lives of those with epilepsy, announced that its management will present at the Leerink Partners 2025 Global Healthcare ...

Kootenai Health is focused on the future of Post Falls when considering the population projection numbers in the next 20 ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders, has been making significant strides in the epilepsy treatment market with its Responsive ...

March 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...

Greetings and welcome to NeuroPace Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.